Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Withdrawn 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1Myeloid 1Lymphoid 1

Conditions

Myelodysplastic Syndromes 6Lymphoma 4Hematologic Neoplasms 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Multiple Myeloma 3Leukemia, Myeloid, Acute 3Leukemia, Myelogenous, Chronic, BCR-ABL Positive 3Leukemia 3Neoplasm, Residual 2Lymphoma, Non-Hodgkin 2Breast Neoplasms 2Triple Negative Breast Neoplasms 1Sarcoma 1Prostatic Neoplasms 1Osteosarcoma 1Neurotoxicity Syndromes 1Neuroblastoma 1Neoplasm Metastasis 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Melanoma 1Lymphoproliferative Disorders 1Lymphoma, B-Cell 1Lymphohistiocytosis, Hemophagocytic 1Lymphatic Diseases 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia, Biphenotypic, Acute 1Immunoproliferative Disorders 1Immune System Diseases 1

Interventions

Brentuximab Vedotin 7dacetuzumab 4Lenalidomide 3Doxorubicin 3Dexamethasone 3spartalizumab 2lintuzumab 2fludarabine 2Vincristine 2Rituximab 2Rifampin 2Prednisone 2Gemcitabine 2Cyclophosphamide 2tanespimycin 1sabatolimab 1pomalidomide 1pirtobrutinib 1fludarabine phosphate 1ficlatuzumab 1daratumumab 1Vinblastine 1Thiotepa 1TAS4464 1Sertraline 1R-CHOP protocol 1Pam2CSK4 acetate and ODN M362 combination 1Midazolam 1Melphalan 1LCL161 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Hematologic Diseases × AP 1903 reagent × Clear all
NCT02786485 2020-10-05

Study of Matched Unrelated Donor T Cell Infusion for Hematologic Malignancies After Allo-HSCT

Bellicum Pharmaceuticals

Phase 1 Withdrawn
LymphoidMyeloidOther hematologic neoplasmPlasma cell

Hematologic Diseases, Leukemia, Lymphoma, Multiple Myeloma, Myelodysplastic Syndromes, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡